Mutabilis
Biotechnology ResearchView the employees at
Mutabilis-
Wandrille Ract-Madoux CEO at Mutabilis
-
Romainville, Île-de-France, France
-
Top 10%
Rémi Lebel Chimiste en synthèse organique chez Mutabilis-
Drancy, Île-de-France, France
-
Rising Star
Damien Bonnard Head of biochemistry/pharmacology at Mutabilis-
Avignon, Provence-Alpes-Côte d'Azur, France
-
Rising Star
Sophia BRIET Assistante de recherche/chimie medicinale chez Mutabilis-
Saint-Leu-la-Forêt, Île-de-France, France
-
Rising Star
Francois Moreau Director of Research at Mutabilis-
Greater Paris Metropolitan Region
-
Top 10%
Overview
Mutabilis is a privately-held French biopharmaceutical company developing novel non-beta-lactam PBP-targeting antibacterial drugs called dabocins to treat the most difficult-to-treat Gram-negative bacterial infections. Dabocins are derived from the non-natural diazabicyclooctane scaffold and show a remarkable stability to beta-lactamase hydrolysis. Mutabilis’ team has unique expertise in the derivatization and characterization of this scaffold. Mutabilis’ pipeline includes EBL-1463, a novel single-agent intravenous antibiotic against carbapenem-resistant Enterobacterales also supported by ENABLE (ND4BB/IMI), and 2G-DAB, a 2nd generation dabocin program supported by the Repair Impact Fund and which aims to discover the next generation dabocin covering both Enterobacterales and non-fermenters. For more information, please visit https://mutabilis.fr/.
-